Circio Holding ASA (”Circio” or ”the Company”) announced, on the 8th of April 2026, that the Company has completed a significantly oversubscribed private placement raising NOK 250m in gross proceeds, directed at new Nordic and international investors. The placement was arranged as a club deal, with the offer price set at NOK 10.80 per share, corresponding to the market price at the opening of the prior trading day, a 5% premium to the 5-day VWAP, and a 20% premium to the 10-day VWAP. A total of 23,148,148 new shares were issued, bringing post-placement NOSH to 238,054,835. A subsequent offering of up to NOK 82.5m at the same subscription price is planned for existing shareholders, bringing total potential gross proceeds to NOK 332.5m and extending Circio’s financial runway into 2030.
A Transformational Financing that Extends the Runway into 2030
Analyst Group views the NOK 250m private placement as a transformational event for Circio, the largest single capital injection in the Company’s history after its repositioning into circular RNA, and one that fundamentally alters the Company’s strategic position. The offer price of NOK 10.80 represents a pronounced re-rating relative to the NOK 1.0 subscription price in the Q1-26 rights issue, reflecting the cumulative impact of preclinical data delivery, partnership activity, and growing industry recognition over the past twelve months. Over this period, Circio has demonstrated up to ~50x enhanced gene expression in the eye and ~40x in the heart using circVec-AAV, entered a fully funded feasibility study with a top-5 global pharmaceutical company in CNS, and expanded the platform into in vivo cell therapy through new research collaborations, a body of work capped by the selection for an oral presentation at ASGCT 2026, which provides the scientific foundation underpinning the increased investor interest reflected in the placement. In Analyst Group’s view, the placement reflects a well-timed decision by the Board to leverage the re-rated share price to secure long-term financial capacity, effectively locking in favorable terms while investor appetite and market conditions allowed. The more than 2-fold oversubscription, at-market pricing with premiums to the 5- and 10-day VWAPs, and the fact that the placement was conducted as a club deal exclusively with new investors, both Nordic and international, signal a meaningful broadening of Circio’s investor base and growing external conviction in circVec as a platform.
In addition, the planned subsequent offering of up to NOK 82.5m, directed at existing shareholders at the same subscription price, would bring total gross proceeds to NOK 332.5m if fully subscribed. According to the Company, the net proceeds from the private placement extend Circio’s financial runway into 2030. Assuming the subsequent offering is fully subscribed, total available capital would amount to approx. NOK 375m, including the NOK 42m cash position at the end of Q1-26, implying an average monthly burn rate of approx. NOK 7–8m over the period, a substantial step-up from the NOK 3.8m per month recorded for FY2025. However, Analyst Group estimates that the burn rate will increase gradually over the coming years as the Company scales its R&D activities, expands headcount, and invests in new infrastructure to advance the preclinical pipeline and capitalize on the Company’s early-mover advantage in circular RNA-based gene and cell therapy.
Moreover, the approx. 65 million warrants from the Q1-26 rights issue remain exercisable in Q2-26 at a strike price corresponding to 80% of the VWAP during 8–22 May 2026. With the near-term runway already secured, any proceeds from the warrant exercise would provide additional financial flexibility to broaden the development program or accelerate existing tracks beyond the current plan. The actual proceeds will depend on the share price during the VWAP reference period, but at current levels, the warrants represent a meaningful source of additional optionality.
An Expanded Development Agenda Backed by a Concentrated Catalyst Pipeline
The strategic rationale for the accelerated investment is rooted in the nature of the platform itself. CircVec’s core value proposition, durable, high-level gene expression across multiple tissue types, addresses a fundamental bottleneck in both AAV gene therapy and the emerging field of in vivo cell therapy, where insufficient expression duration and stability remain key limiting factors. In AAV gene therapy, circVec has demonstrated the ability to materially enhance expression in heart, eye, and CNS tissue, broadening the platform’s relevance well beyond any single indication. In in vivo cell therapy, an emerging but as yet clinically unvalidated field where the objective is to reprogram immune cells directly in the body rather than through costly and complex ex vivo manufacturing, durable expression duration is widely regarded as a key technical requirement. CircVec’s demonstrated multi-month expression profile could prove relevant in this context if the broader approach is validated. The fact that circVec sits at the intersection of these two rapidly expanding fields, and that the financing now allows Circio to pursue both in parallel, is, in Analyst Group’s view, central to understanding the strategic logic of the placement.
The proceeds from the capital raise will be used to accelerate circVec-AAV gene therapy development in heart, eye, and CNS, with the explicit ambition to select one or more clinical candidates. In parallel, the Company will scale up the in vivo CAR-T cell therapy program (circVec-LNP) through new infrastructure and dedicated personnel, and strengthen the Company’s business development activities. Analyst Group notes that the reference to clinical candidate selection represents a meaningful escalation of the Company’s stated ambition, and if achieved, would move circVec materially closer to licensing-relevant maturity. The commitment of dedicated resources to the in vivo CAR program also signals that this track is being elevated beyond exploratory collaborations, consistent with the recently announced research collaboration with United Immunity on in vivo CAR-M therapy.
Analyst Group considers these ambitions to be supported by a broad near-term catalyst pipeline: the ASGCT oral presentation in May 2026, in vivo CAR targeted T-cell delivery data (Q2-26), AAV-circVec wet AMD disease-model efficacy data (Q2/Q3-26), CNS PoC data from the ongoing big pharma collaboration (Q3/Q4-26), and Danon heart disease-model efficacy data (Q4-26). Collectively, positive outcomes across these readouts would materially strengthen Circio’s position in licensing discussions and could serve as triggers for deepened partner engagement over the coming quarters.
In summary, Analyst Group views the NOK 250m private placement as a defining moment for Circio. The combination of a substantially strengthened balance sheet, an expanded development agenda spanning AAV gene therapy and in vivo cell therapy, and a concentrated pipeline of near-term data readouts creates a fundamentally different strategic platform from which the Company can operate. By securing multi-year financial capacity on favorable terms, with the warrant exercise in Q2-26 providing further optionality, Circio is positioned to advance circVec toward clinical candidate selection and licensing discussions from a position that few preclinical-stage companies can match. With multiple data readouts expected across 2026 and a high-profile ASGCT presentation approaching, Analyst Group considers Circio well-positioned to build on the scientific momentum that attracted this level of investor commitment and to convert it into deepened partner engagement and continued platform validation.
We will return with an updated equity research report of Circio following the FY2025 report.
